Transforming Physician Identification: Leverage Real-Time Data to Reach Every Eligible Patient

Webinar Oncology & Hematology
Date: June 2025
Time: N/A
Location: Online

Pharma and biotech companies today face significant hurdles with identifying physicians that are treating patients relevant to their therapies. It is also challenging to cut through the noise and capture the attention of physicians at just the right time, before they make treatment decisions.

Join us for this one hour deep dive with a panel of experts and industry leaders to gain valuable insights and guidance on diagnostic and precision medicine testing. Learn how to revolutionize your approach to physician engagement for enabling more informed treatment decisions, fewer missed patients, and the chance for every eligible patient to receive optimal therapy.

We explored:
  • Strategies and tactics that optimize your launch and brand strategy to improve future commercial projections

  • Why physician identification and engagement within 24 hours following a positive test result is key to enabling a therapy to succeed

  • Steps for achieving above industry standard physician and key stakeholder engagement rates

  • Ways to close the gap between testing and clinical response, driving peer-to-peer, just-in-time discussions that drive greater therapy adoption
  • How to leverage timely, omnichannel engagement to enhance field force planning and increase prescriptions

     

Speakers:
Jordan Clark
Chief Data Officer

As Chief Data Officer at Diaceutics, Jordan spearheads comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to our clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimizing precision medicine. Jordan's

academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a hematology scientist, underscore his expertise. Additionally, his renowned proficiency in bioinformatics and biomarker testing, honed through his involvement with UK NEQAS, further solidifies his leadership in the field.

Connect
Kenneth Ruppel
VP Scientific & Medical Services
Ken Ruppel is the Vice President of Scientific and Medical Services at Diaceutics, where he plays a pivotal role in driving innovation and supporting global leaders in the development of impactful commercialization strategies for the launch of precision medicines. With over 25 years of experience in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets, Ken brings a wealth of expertise and strategic vision to Diaceutics. Connect
Gunjan Aggarwal
Executive Director, (Insights and Decision Science), Novartis

Gunjan Aggarwal is a healthcare data strategist with extensive experience in digital transformation, analytics, and precision medicine. As Executive Director at Novartis, she leads initiatives that enhance data-driven marketing and patient-centric solutions. Passionate about reimagining healthcare, Gunjan applies AI and emerging technologies to drive operational efficiency and innovation.

Connect
Michelle Shiller, PhD.
Medical Director Cancer Genetics and Precision Medicine Texas Cancer Interception Institute

Dr. Michelle Shiller is a recognized leader in integrating molecular diagnostics and precision medicine into clinical practice. She is board certified in Anatomic, Clinical, and Molecular Genetic Pathology, with advanced training from the Mayo Clinic. A passionate advocate for clinical education, Dr. Shiller is committed to empowering physicians with the knowledge and confidence to make timely, informed treatment decisions—especially in complex and evolving areas like oncology and rare disease.

Connect

Submit your details to view the recording

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network ®

Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.